Serplulimab is the UK’s first licensed anti-PD-1 monoclonal antibody for this aggressive form of lung cancer. It is indicated for adults with untreated ES-SCLC, where the disease has spread ...

UK MHRA approves Accord Healthcare’s anti-PD-1 monoclonal antibody, serplulimab to treat aggressive form of SCLC: United Kingdom Monday, June 23, 2025, 09:00 Hrs [IST] The Medic ...

UK MHRA approves Accord Healthcare’s anti-PD-1 monoclonal antibody, serplulimab to treat aggressive form of SCLC ... SCLC is a fast-growing cancer that typically develops in the airways of the lungs.

When small-cell lung cancer (SCLC) has spread to distant parts of the body, it’s classified as extensive-stage, which applies ...

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved Accord Healthcare’s Henlius-partnered Hetronifly ...

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved Hetronifly (serplulimab) to treat adults ...

ES-SCLC is a form of lung cancer accounting for one in eight lung cancer cases in the UK. It is an aggressive disease that progresses rapidly, with a significant negative impact on the quality of ...

So now we live in a time when Americans in power ignore the Constitution and curtail freedom of speech, freedom of assembly ...

Bristol Myers Squibb (BMS) is joining forces with BioNTech in a deal that could surpass $11bn as the two drugmakers look to take on the dominance of MSD’s Keytruda (pembrolizumab) in solid tumour ...

The FDA has started a priority review of Amgen’s tarlatamab for small cell lung cancer (SCLC), the lead drug in the company’s pipeline of bispecific T-cell engager (BiTE) drugs for solid tumours.

Read How Can  Christians Stand Firm in a Culture of Confusion? by Judy McEachran and more articles about Church on ...